National Medicines Policy in retrospective: a review of (almost) 20 years of implementation.

Cien Saude Colet

Departamento de Política de Medicamentos e Assistência Farmacêutica, Escola Nacional de Saúde Pública, Fiocruz. R. Leopoldo Bulhões 1480, Manguinhos. 21041-210 Rio de Janeiro RJ Brasil.

Published: August 2017

Pharmaceutical services and the formulation of a medicines policy are SUS areas ensured by the organic health care law 8,080/90. Thus, after a widely participative process, involving stakeholders, the National Medicines Policy (NMP) was approved in 1998 by Ordinance 3,916.The NMP presents directives and priorities, aligned with organic health care law, which should guide the federal, states and municipals entities actions to achieve the policy goals. Considering almost 20 years of the NMP, this paper took stock discussed some of the directives in light of the SUS principles. It was not the objective to provide an exhaustive review of all the activities performed during this period. The authors tried to get close to those that have brought advances and dilemmas, with potential risk of regression. Efforts to implement an ambitious agenda applied to pharmaceutical services were identified. This agenda tried to deal with different challenges like the dynamics of the pharmaceutical market and the operation of pharmaceutical services to guarantee the supply of medicines aligned with principles and directives of SUS.

Download full-text PDF

Source
http://dx.doi.org/10.1590/1413-81232017228.02432017DOI Listing

Publication Analysis

Top Keywords

medicines policy
12
pharmaceutical services
12
national medicines
8
organic health
8
health care
8
care law
8
policy
4
policy retrospective
4
retrospective review
4
review years
4

Similar Publications

Background: Needs-based care is a central concern of healthcare policy. A European comparison of the utilisation of medical services can help to assess national data and identify the need for action.

Methods: This article describes indicators on the utilisation of outpatient and inpatient services, medical examinations and the use of medicines from the third wave of the European Health Interview Survey (EHIS 3) and compares the results from Germany with the European averages.

View Article and Find Full Text PDF
Article Synopsis
  • The paper reviews various cost containment policies aimed at controlling pharmaceutical spending by either regulating the industry or influencing consumer demand.
  • A narrative literature review highlights that governments have adopted diverse strategies like cost-sharing, value-based pricing, and the promotion of generics, but their effectiveness varies between healthcare systems and can negatively affect patients.
  • The conclusion emphasizes the need for thorough evaluation of these policies to ensure their success, as many lack strong evidence of cost-effectiveness and suggest that further research is essential to create tailored solutions that maintain affordability, fairness, and sustainability in healthcare.
View Article and Find Full Text PDF

The Attitudes Toward Polypharmacy and Willingness to Deprescribe Among Patients with Multimorbidity in Rural Areas of Shandong Province in China: A Cross-Sectional Study.

Patient Prefer Adherence

December 2024

Center for Health Management and Policy Research, School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan, People's Republic of China.

Purpose: Multimorbidity and polypharmacy have emerged as significant global issues, heightening the risks of potentially inappropriate medications (PIMs). This necessitates medication optimization through deprescribing. Understanding patients' decision-making preferences regarding medication cessation is crucial for mitigating medication-related risks.

View Article and Find Full Text PDF

Wnt signaling is a critical pathway implicated in cancer development, with Frizzled proteins, particularly FZD10, playing key roles in tumorigenesis and recurrence. This study focuses on the potential of repurposed FDA-approved drugs targeting FZD10 as a therapeutic strategy for nasopharyngeal carcinoma (NPC). The tertiary structure of human FZD10 was constructed using homology modeling, validated by Ramachandran plot and ProQ analysis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!